In October 2020, Cascade announced the completion of nearly 100 million yuan pre-A round of financing to promote the systematic preclinical research and clinical stage research of innovative varieties for the treatment of cholic acid metabolic diseases under research. This round of financing is jointly invested by Gaorong Kangteng, Gaorong Kangyong, Jiuyou, Zhongshan Zhongkechuang Pharmaceutical Venture capital and Jiaxing Jinhu No. 6.
